Filter Results :

Your search for Antibodies returned 61 reports

Sort by


Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

15 Sep 2016  |  Published by:  MarketsandMarkets
The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, rising healthcare expenditure, and increased access to medical insurance in developed countries...

$ 5,650.00

Read More

Global Breast Cancer Monoclonal Antibodies Market 2016-2020

06 Sep 2016  |  Published by:  Technavio-Infiniti Research
About Breast Cancer mAbsBreast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled ...

$ 2,500.00

Read More

Global Monoclonal Antibodies Market 2016-2020

20 Jul 2016  |  Published by:  Technavio-Infiniti Research
About Monoclonal Antibodies Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to ...

$ 2,500.00

Read More

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

03 Jun 2016  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory & Other Diseases evaluates the competitive landscape of bispecific therapeutic antibodies for treatment of cancer, anti-inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, ...

$ 560.63

Read More

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies

25 May 2016  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting CD20 in comparison with originator anti-CD20 antibodies to treat solid tumors as well as inflammatory...

$ 336.38

Read More

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies

25 May 2016  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the ...

$ 1,457.63

Read More

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies

25 May 2016  |  Published by:  La Merie Business Intelligence
Humira, Enbrel and Remicade were the three best selling blockbuster biologics in the year 2015. Together with Simponi and Cimzia, combined sales of all five anti-TNF antibodies in the year 2015 were US$ 36 bln (+3.9% vs previous year), ahead of combined sales of all cancer antibodies. Marketin...

$ 560.63

Read More

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies

25 May 2016  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting Her2 in comparison with originator anti-Her2 antibodies to treat solid tumors as of May 2016. Purchas...

$ 336.38

Read More

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies

25 May 2016  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting epithelial growth factor receptor (EGF-R) in comparison with originator anti-EGF-R antibodies to treat so...

$ 280.31

Read More

T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

11 May 2016  |  Published by:  La Merie Business Intelligence
Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Des...

$ 2,400.00

Read More

Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021 - Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment

04 Apr 2016  |  Published by:  Kelly Scientific Publications
Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021 Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment This newly published report is a global industry ...

$ 4,260.75
$ 3,834.68
( Save 10% )

Read More

Global Anti-CD20 Monoclonal Antibodies Industry 2016 Market Research Report

18 Mar 2016  |  Published by:  9Dimen Research
2016 Global Anti-CD20 Monoclonal Antibodies Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Anti-CD20 Monoclonal Antibodies industry, focusing on the main regions (North America, Europe and Asia) and the main count...

$ 2,850.00

Read More

Blockbuster Biologics 2015: Sales of Recombinant Therapeutic Antibodies & Proteins

01 Mar 2016  |  Published by:  La Merie Business Intelligence
This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2015. Sales data were obtained from company publications and refer to branded products originating from companies based in reg...

$ 134.55

Read More

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

01 Feb 2016  |  Published by:  La Merie Business Intelligence
This Competitive Intelligence Report provides a competitor evaluation in the field of approved and investigational vaccines and therapeutics against one or more serotypes of Dengue Virus for prophylaxis or treatment of Dengue fever as of February 2016. The report covers live attenuated or whol...

$ 224.25

Read More

Engineered Bispecific Antibodies (BsAb) Novel Approaches & Pipeline Insights, 2016

01 Jan 2016  |  Published by:  DelveInsight
Summary “Engineered Bispecific Antibodies (BsAb) Novel Approaches & Pipeline Insights, 2016” emphasizes on the novel bispecific antibodies technologies in research and development. The report enlists company, target antigens, phase and indication specific R&D pipelines of Bispecifc ...

$ 2,750.00

Read More
Total 61 records.